☆ 4.7 Review

Treat-to-Target in Systemic Lupus Erythematosus: Reality or Pipe Dream

JOURNAL OF CLINICAL MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Rheumatology

New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review

Renaud Felten et al.

Summary: Despite available therapies, persistently active and corticosteroid-dependent Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. This systematic review provides an updated view of targeted therapies currently in clinical development in SLE, with a special focus on the most promising ones.

JOINT BONE SPINE (2023)

添加到收藏夹

Article Immunology

Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus

Julius Lindblom et al.

Summary: This study aimed to investigate the transcriptome, eQTLs, and serological markers in SLE patients compared to healthy controls. The analysis revealed the significance of interferon signaling pathways and downregulation of lymphocyte signaling cluster in renal activity. Upregulation of interferon-related genes indicated hematological activity and vasculitis. Modulation of interferon, STAT1, PLK1, B and plasma cell signatures showed promise as viable approaches to treat SLE.

JOURNAL OF AUTOIMMUNITY (2023)

添加到收藏夹

Article Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S. Smolen et al.

Summary: This study provides an update on the management recommendations for rheumatoid arthritis (RA) based on the latest developments in the field. The recommendations cover various aspects including medication use, combination therapy, treatment strategies, and dose reduction. The consensus was reached on 5 overarching principles and 11 specific recommendations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Article Rheumatology

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus

Eric F. Morand et al.

Summary: A post hoc analysis reveals that treatment with anifrolumab in patients with SLE leads to earlier, more frequent, and more sustained attainment of LLDAS. LLDAS is highly associated with responses measured by BICLA and SRI(4).

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Review Rheumatology

Prevalence, Predictors, and Prognostic Benefits of Remission Achievement in Patients With Systemic Lupus Erythematosus: A Systematic Review

Ziyi Yang et al.

Summary: This study systematically reviewed and evaluated the prevalence, potential predictors, and prognostic benefits of remission achievement in patients with systemic lupus erythematosus (SLE). The findings suggest that achieving remission is an attainable goal for SLE patients and is associated with better prognosis.

ARTHRITIS CARE & RESEARCH (2022)

添加到收藏夹

Review Rheumatology

Treat-to-target in systemic lupus erythematosus: advancing towards its implementation

Agner R. Parra Sanchez et al.

Summary: The treat-to-target (T2T) concept, which involves choosing a specific target, evaluating the outcomes, and taking action accordingly, has been successful in improving outcomes for patients with diabetes, hypertension, and rheumatoid arthritis. However, the application of this approach in systemic lupus erythematosus (SLE) requires measurable and achievable outcomes, as well as more therapeutic options. Currently, the available therapeutic options for SLE are limited, and there is a need for more effective and safer treatments. Fortunately, there have been significant advancements in clinical trial activity for SLE, especially with the development of novel therapies. With these expected advancements, it is likely that a wider range of treatments will be available for SLE in the near future, allowing for the routine implementation of a treat-to-target approach.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Edward M. Vital et al.

Summary: This study characterizes the efficacy and safety of anifrolumab in patients with moderate-to-severe SLE. It shows that anifrolumab has consistent efficacy and safety across different subgroups of patients. However, the limited sample size in some subgroups limits the conclusions about treatment benefit with anifrolumab.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Self-Reported Anxiety and Depression in a Monocentric Cohort of Patients With Systemic Lupus Erythematosus: Analysis of Prevalence, Main Determinants, and Impact on Quality of Life

Elena Elefante et al.

Summary: This study analyzed the prevalence of self-reported anxiety and depression in patients with Systemic Lupus Erythematosus (SLE) and its impact on quality of life. The results showed that anxiety and depression symptoms are frequent in SLE patients and have a significant negative impact on their quality of life and perception of disease activity.

FRONTIERS IN MEDICINE (2022)

添加到收藏夹

Article Rheumatology

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis

Takehiro Nakai et al.

Summary: A retrospective study evaluated the risk factors and flare rates of glucocorticoid discontinuation in SLE patients. The study found that gradual tapering of glucocorticoids can often be achieved in SLE patients, even with prior severe organ involvement, especially when the disease is clinically and serologically stable.

LUPUS SCIENCE & MEDICINE (2022)

添加到收藏夹

Article Rheumatology

Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Manuel Francisco Ugarte-Gil et al.

Summary: This study investigated the impact of different definitions of remission and low disease activity on damage accrual in patients with lupus. The results show that both remission on-treatment and off-treatment, as well as low disease activity and modified lupus low disease activity, are associated with less damage accrual.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial

Johanna Mucke et al.

Summary: This study aims to assess the implementation of a 'treat-to-target' concept in clinical care to minimize damage accrual and improve HRQoL in SLE patients. Comparing remission and LLDAS will help identify the target with the best benefit-risk ratio, concerning attainability, adverse events, and damage. The emphasis on shared decision-making will strengthen patient autonomy and improve both their satisfaction and medical condition.

LUPUS SCIENCE & MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Long-term remission in patients with systemic lupus erythematosus

Mozhdeh Nikfar et al.

Summary: This study investigated the remission status and long-term outcomes of SLE patients, finding that sustained remission is negatively associated with organ damage. Predictors of remission include treatment adherence and age.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Brad H. Rovin et al.

Summary: This study evaluated the efficacy and safety of voclosporin for the treatment of lupus nephritis, showing a superior complete renal response rate with voclosporin in combination with MMF and low-dose steroids compared to MMF and low-dose steroids alone. The safety profile was comparable between the two groups. This finding represents an important advancement in the treatment of patients with active lupus nephritis.

LANCET (2021)

添加到收藏夹

Article Rheumatology

2021 DORIS definition of remission in SLE: final recommendations from an international task force

Ronald F. van Vollenhoven et al.

Summary: Through systematic literature reviews and data analysis, the DORIS Task Force reached a consensus on a single definition of remission in SLE, recommending criteria based on specific clinical indicators and medication dosage.

LUPUS SCIENCE & MEDICINE (2021)

添加到收藏夹

Article Rheumatology

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

Konstantinos Tselios et al.

Summary: The study found that gradual glucocorticoid withdrawal in patients with clinically quiescent SLE is safe and associated with fewer clinical flares and less damage accrual at 24 months compared to those maintaining a low prednisone dose.

ACR OPEN RHEUMATOLOGY (2021)

添加到收藏夹

Review Rheumatology

Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis

Konstantinos Tselios et al.

Summary: The study aimed to evaluate the response to placebo in non-renal, non-neuropsychiatric SLE patients. It was found that more than one-third of placebo-treated patients achieved their respective primary end points in RCTs with biologics, with a higher response rate for certain end points like SRI-4, but decreasing with more stringent end points.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus

Chanakya Sharma et al.

ARTHRITIS CARE & RESEARCH (2020)

添加到收藏夹

Article Rheumatology

Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort

Manuel F. Ugarte-Gil et al.

ARTHRITIS CARE & RESEARCH (2020)

添加到收藏夹

Article Rheumatology

Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus

Ai Li Yeo et al.

ARTHRITIS CARE & RESEARCH (2020)

添加到收藏夹

Article Rheumatology

Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial

Alexis Mathian et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Review Medicine, General & Internal

Treat-to-target in systemic lupus erythematosus: Where are we?

Roberto Rios-Garces et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Rheumatology

Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort

Francesca Saccon et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Review Rheumatology

2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis

Antonis Fanouriakis et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Rheumatology

Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naive patients with systemic lupus erythematosus

Dai Gao et al.

RHEUMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis

Irene B. Murimi-Worstell et al.

BMJ OPEN (2020)

添加到收藏夹

Article Medicine, General & Internal

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

Richard Furie et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Rheumatology

Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus

Elena Elefante et al.

ARTHRITIS RESEARCH & THERAPY (2020)

添加到收藏夹

Article Rheumatology

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Christel Wilkinson et al.

ARTHRITIS RESEARCH & THERAPY (2020)

添加到收藏夹

Review Rheumatology

Prediction of prognosis and renal outcome in lupus nephritis

Ioannis Parodis et al.

LUPUS SCIENCE & MEDICINE (2020)

添加到收藏夹

Article Rheumatology

Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus

Elena Elefante et al.

RMD OPEN (2020)

添加到收藏夹

Article Rheumatology

Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study

Serena Fasano et al.

CLINICAL RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Shereen Oon et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

添加到收藏夹

Article Rheumatology

Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort

G. S. Alarcon et al.

LUPUS (2019)

添加到收藏夹

Review Rheumatology

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Antonis Fanouriakis et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

添加到收藏夹

Review Immunology

Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts

Guillermo Ruiz-Irastorza et al.

AUTOIMMUNITY REVIEWS (2019)

添加到收藏夹

Article Rheumatology

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus

Ioannis Parodis et al.

RHEUMATOLOGY (2019)

添加到收藏夹

Editorial Material Rheumatology

Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?

Eric F. Morand et al.

JOURNAL OF RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

Predictors of predominant Lupus Low Disease Activity State (LLDAS-50)

H. Babaoglu et al.

LUPUS (2019)

添加到收藏夹

Article Rheumatology

The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus

D. P. E. Margiotta et al.

LUPUS (2019)

添加到收藏夹

Article Rheumatology

Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre

Rudra Prosad Goswami et al.

CLINICAL RHEUMATOLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

Brad H. Rovin et al.

KIDNEY INTERNATIONAL (2019)

添加到收藏夹

Article Rheumatology

The relationship between remission and health-related quality of life in a cohort of SLE patients

Michel W. P. Tsang-A-Sjoe et al.

RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

How can we define low disease activity in systemic lupus erythematosus?

Konstantinos Tselios et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)

添加到收藏夹

Article Rheumatology

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience

Chiara Tani et al.

RMD OPEN (2019)

添加到收藏夹

Article Rheumatology

Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort

Michelle Petri et al.

ARTHRITIS & RHEUMATOLOGY (2018)

添加到收藏夹

Review Rheumatology

Systemic lupus erythematosus: state of the art on clinical practice guidelines

Farah Tamirou et al.

RMD OPEN (2018)

添加到收藏夹

Article Rheumatology

Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort

Chiara Tani et al.

LUPUS SCIENCE & MEDICINE (2018)

添加到收藏夹

Article Rheumatology

Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission

Margherita Zen et al.

ANNALS OF THE RHEUMATIC DISEASES (2018)

添加到收藏夹

Article Rheumatology

Remission in systemic lupus erythematosus: durable remission is rare

Theresa R. Wilhelm et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

添加到收藏夹

Article Rheumatology

The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients

Margherita Zen et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

添加到收藏夹

Article Rheumatology

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

Ronald van Vollenhoven et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

添加到收藏夹

Article Rheumatology

Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus

Michel W. P. Tsang-A-Sjoe et al.

RHEUMATOLOGY (2017)

添加到收藏夹

Review Rheumatology

Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review

Pavandeep Mehat et al.

ARTHRITIS CARE & RESEARCH (2017)

添加到收藏夹

Article Rheumatology

Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?

Michelle R. Ugolini-Lopes et al.

LUPUS SCIENCE & MEDICINE (2017)

添加到收藏夹

Article Rheumatology

Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus

Matteo Piga et al.

ARTHRITIS RESEARCH & THERAPY (2017)

添加到收藏夹

Article Rheumatology

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

Kate Franklyn et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

添加到收藏夹

Review Rheumatology

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Josef S. Smolen et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

添加到收藏夹

Article Rheumatology

Prolonged remission in Caucasian patients with SLE: prevalence and outcomes

Margherita Zen et al.

ANNALS OF THE RHEUMATIC DISEASES (2015)

添加到收藏夹

Article Rheumatology

Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials Lessons Learned from the Euro-Lupus Nephritis Cohort

Maria Dall'Era et al.

ARTHRITIS & RHEUMATOLOGY (2015)

添加到收藏夹

Article Rheumatology

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial

Farah Tamirou et al.

LUPUS SCIENCE & MEDICINE (2015)

添加到收藏夹

Review Rheumatology

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

Ronald F. van Vollenhoven et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

添加到收藏夹

Review Rheumatology

Treat to Target in Rheumatoid Arthritis

Daniel H. Solomon et al.

ARTHRITIS & RHEUMATOLOGY (2014)

添加到收藏夹

Article Rheumatology

Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort

Z. Abou Zahr et al.

LUPUS (2013)

添加到收藏夹

Article Public, Environmental & Occupational Health

Incidence of and Risk Factors for Adverse Cardiovascular Events Among Patients With Systemic Lupus Erythematosus

Laurence S. Magder et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2012)

添加到收藏夹

Article Rheumatology

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie et al.

ARTHRITIS AND RHEUMATISM (2011)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra V. Navarra et al.

LANCET (2011)

添加到收藏夹

Article Rheumatology

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

J. Nossent et al.

LUPUS (2010)

添加到收藏夹

Article Rheumatology

Predictors of major infections in systemic lupus erythematosus

Guillermo Ruiz-Irastorza et al.

ARTHRITIS RESEARCH & THERAPY (2009)

添加到收藏夹

Article Rheumatology

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

S. M. M. Verstappen et al.

ANNALS OF THE RHEUMATIC DISEASES (2007)

添加到收藏夹

Article Medicine, General & Internal

Comparison of treatment strategies in early rheumatoid arthritis - A randomized trial

Yvonne P. M. Goekoop-Ruiterman et al.

ANNALS OF INTERNAL MEDICINE (2007)

添加到收藏夹

Article Medicine, General & Internal

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

C Grigor et al.

LANCET (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.